Literature DB >> 27221704

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.

Deepak Mittal1, Debottam Sinha2, Deborah Barkauskas3, Arabella Young1, Murugan Kalimutho4, Kimberley Stannard3, Franco Caramia5, Benjamin Haibe-Kains6, John Stagg7, Kum Kum Khanna4, Sherene Loi5, Mark J Smyth8.   

Abstract

Adenosine plays an important role in inflammation and tumor development, progression, and responses to therapy. We show that an adenosine 2B receptor inhibitor (A2BRi) decreases both experimental and spontaneous metastasis and combines with chemotherapy or immune checkpoint inhibitors in mouse models of melanoma and triple-negative breast cancer (TNBC) metastasis. Decreased metastasis upon A2BR inhibition is independent of host A2BR and lymphocytes and myeloid cells. Knockdown of A2BR on mouse and human cancer cells reduces their metastasis in vivo and decreases their viability and colony-forming ability, while transiently delaying cell-cycle arrest in vitro The prometastatic activity of adenosine is partly tumor A2BR dependent and independent of host A2BR expression. In humans, TNBC cell lines express higher A2BR than luminal and Her2(+) breast cancer cell lines, and high expression of A2BR is associated with worse prognosis in TNBC. Collectively, high A2BR on mouse and human tumors promotes cancer metastasis and is an ideal candidate for therapeutic intervention. Cancer Res; 76(15); 4372-82. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27221704     DOI: 10.1158/0008-5472.CAN-16-0544

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Authors:  L Buisseret; S Pommey; B Allard; S Garaud; M Bergeron; I Cousineau; L Ameye; Y Bareche; M Paesmans; J P A Crown; A Di Leo; S Loi; M Piccart-Gebhart; K Willard-Gallo; C Sotiriou; J Stagg
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

3.  On the G protein-coupling selectivity of the native A2B adenosine receptor.

Authors:  Zhan-Guo Gao; Asuka Inoue; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2017-12-07       Impact factor: 5.858

4.  CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.

Authors:  Bruna Cerbelli; Andrea Botticelli; Annalinda Pisano; Angelina Pernazza; Domenico Campagna; Alessandro De Luca; Paolo Antonio Ascierto; Maria Gemma Pignataro; Maria Pelullo; Carlo Della Rocca; Paolo Marchetti; Lucio Fortunato; Leopoldo Costarelli; Giulia d'Amati
Journal:  Virchows Arch       Date:  2019-12-18       Impact factor: 4.064

Review 5.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

Review 6.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation.

Authors:  Seyyed Mehdi Jafari; Hamid Reza Joshaghani; Mojtaba Panjehpour; Mahmoud Aghaei
Journal:  Cell Oncol (Dordr)       Date:  2017-12-07       Impact factor: 6.730

Review 8.  The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Authors:  Nick van Dijk; Samuel A Funt; Christian U Blank; Thomas Powles; Jonathan E Rosenberg; Michiel S van der Heijden
Journal:  Eur Urol       Date:  2018-09-28       Impact factor: 20.096

9.  Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.

Authors:  Kyohei Nakamura; Mika Casey; Harald Oey; Frank Vari; John Stagg; Maher K Gandhi; Mark J Smyth
Journal:  Leukemia       Date:  2020-04-08       Impact factor: 11.528

Review 10.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.